Vectorite Biomedical

Vectorite Biomedical CapEx/OCF

The CapEx to Operating Cash Flow Ratio of Vectorite Biomedical (4170.TWO) as of Nov 5, 2026 is -69.09 %. In the previous year, CapEx to Operating Cash Flow Ratio was -24.68 % — a change of 179.92% (lower).

CapEx/OCF

-69.09 %

YoY

179.92%

Last updated:

CapEx to Operating Cash Flow Ratio of Vectorite Biomedical is 2025 -69.09 % . CapEx to Operating Cash Flow Ratio of Vectorite Biomedical was 2024 -24.68 % . It decreases by 179.92% lower compared to the previous year.

The Vectorite Biomedical CapEx/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CapEx/OCF
Date
CapEx/OCF
Jan 1, 2018
-48.87 TWD
Jan 1, 2019
-6.87 TWD
Jan 1, 2020
-2.09 TWD
Jan 1, 2021
-2.73 TWD
Jan 1, 2022
6.04 TWD
Jan 1, 2023
366.33 TWD
Jan 1, 2024
-24.68 TWD
Jan 1, 2025
-69.09 TWD
The Vectorite Biomedical CapEx/OCF history
YEARCapEx/OCFYoY
-69.09 %+179.92%
-24.68 %-106.74%
366.33 %+5,965.12%
6.04 %-321.39%
-2.73 %+30.58%
-2.09 %-69.57%
-6.87 %-85.95%
-48.87 %-185.74%
57.00 %-267.10%
-34.11 %-97.40%
-1,313.84 %+11,261.66%
-11.56 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Vectorite Biomedical Stock analysis

What does Vectorite Biomedical do? Xinpin Biomedical Co., Ltd. established Xinpin Biomedical Group with the concept of “preventing problems before it happens” and is headquartered in Taipei, New Taipei. The firm offers a range of services including immune cell collection, processing and storage, cell preparation safety testing, anti-cancer immunity testing, original design manufacturer or contract development and manufacturing organization services, related medical consulting, and laboratory quality management. Its product portfolio features dendritic cell vaccines and natural killer cell preparations designed for cancer treatment. Products are mainly sold domestically. Vectorite Biomedical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vectorite Biomedical stock

CapEx to Operating Cash Flow Ratio of Vectorite Biomedical is -69.09 % in 2025.

CapEx to Operating Cash Flow Ratio of Vectorite Biomedical changed from -24.68 % to -69.09 %, representing a 179.92% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of CapEx to Operating Cash Flow Ratio Vectorite Biomedical since 2006 – with annual values, charts, and detailed analysis.

The CapEx/OCF ratio shows what percentage of operating cash flow is reinvested in capital assets. Lower ratios indicate more free cash available for shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare CapEx to Operating Cash Flow Ratio's Vectorite Biomedical with sector peers and the industry average to assess whether it is attractive.

To evaluate CapEx to Operating Cash Flow Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for CapEx to Operating Cash Flow Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Vectorite Biomedical

All Key Metrics — Vectorite Biomedical